Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

May 15, 2007

Primary Completion Date

August 24, 2009

Study Completion Date

October 26, 2010

Conditions

HIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

DRUG

Vicriviroc

One tablet of vicriviroc 30 mg once daily.

DRUG

Placebo

One tablet of placebo once daily.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00474370 - Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED) | Biotech Hunter | Biotech Hunter